The newest deal is THREAD’s third acquisition announcement in lower than six months. In January, the corporate mentioned it had scooped up inVibe, which goals to make use of affected person voice information for analysis. THREAD additionally acquired Modus Outcomes, a analysis design consultancy, in November.
CureClick affords a platform for ambassadors representing totally different illnesses or situations to search out open medical trials and share details about find out how to be a part of on social media.
“One of many benefits of decentralization is partaking sufferers from broader geographic areas and extra various backgrounds into medical analysis in order that trials higher signify real-world populations,” John Reites, CEO of THREAD, mentioned in a press release.
“CureClick helps our prospects make their medical trials extra accessible and inclusive whereas higher supporting our present base of premier recruitment-focused companions who can leverage a brand new market for his or her providers.”
WHY IT MATTERS
THREAD is positioning the acquisition as a method to extra simply enroll members in decentralized medical trials.
“Integrating CureClick’s know-how within the THREAD platform means a participant can rapidly and simply go from being completely unaware of a probably life-altering medical trial to being enrolled and taking part in that trial,” Nico Coetzee, chief advertising officer at CureClick, mentioned in a press release. Coetzee will function head of recruitment for THREAD. “It is a highly effective step ahead to modernizing analysis.”
THE LARGER TREND
Like different digital care instruments, decentralized medical trials turned extra mainstream through the COVID-19 pandemic as researchers and trial members aimed to restrict in-person interplay.
“This dialogue turned very operational, very tactical. How do you do that? What are the advantages? How do I put it into the research I’ve at the moment?” THREAD’s Reites mentioned on HIMSSCast final yr. “The pandemic accelerated that thought course of. It additionally offered a extremely energetic requirement and wish for decentralized research.”
One other decentralized medical trial platform, Medable, raised a whopping $304 million Collection D funding in October final yr. Lightship additionally introduced a $40 million funding spherical across the identical time.
DCT firm Science 37 went public in 2021 by way of a merger with a particular objective acquisition firm. In the meantime Verily, Alphabet’s life science subsidiary, acquired medical trial administration firm SignalPath final yr to additional construct out Baseline, its medical trial platform that features know-how for decentralized and hybrid trials.